Olfactory Dysfunction in β Thalassemia Major Patients Treated With Iron-Chelating Agents

3Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Ocular and ophthalmological adverse effects may be seen in β-thalassemia major (BTM) patients treated with regular blood transfusions and iron-chelating agents. We hypothesized that olfactory dysfunction may be present in this population. In this study, we aimed to investigate olfactory dysfunction in patients with BTM and determine the etiological factors. A total of 43 patients with BTM were included in the study. Forty-three patients without any nasal complaints, history of facial trauma, or nasal surgery were included as the controls. All participants had nasal endoscopy. The iron-chelating agents used, their duration of use, as well as hemoglobin and ferritin levels of the BTM patients were recorded. Sniffin’ Sticks test (SST) was used to assess olfactory functions, and BTM and control groups were compared for the results. The correlations of SST scores with the other study parameters were analyzed. Eight (18.6%) of 43 patients in the BTM group had hyposmia while none of the patients in the control group had hyposmia (P

Cite

CITATION STYLE

APA

Derin, S., Erdogan, S., Sahan, M., Azik, M. F., Derin, H., Topal, Y., & Topal, H. (2019). Olfactory Dysfunction in β Thalassemia Major Patients Treated With Iron-Chelating Agents. Ear, Nose and Throat Journal, 98(8), NP125–NP130. https://doi.org/10.1177/0145561319840079

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free